Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • In metastatic RCC, sunitinib plus gefitinib demonstrated comparable efficacy to sunitinib monotherapy with an acceptable safety profile. Dosing, pharmacokinetic profile, and safety support study of sunitinib plus an epidermal growth factor receptor inhibitor in other tumor types.

publication date

  • December 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/COC.0b013e3181c4454d

PubMed ID

  • 20142724

Additional Document Info

start page

  • 614

end page

  • 8

volume

  • 33

number

  • 6